{'fraction_non_alphanumeric': 0.04145077720207254, 'fraction_numerical': 0.0034542314335060447, 'mean_word_length': 6.073170731707317, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Reducing the side effects of chemotherapy.

The administration of 5-fluorouracil (5-FU), folinic acid (FA) and oxaliplatin (FOLFOX regimen) represents “standard of care” first line treatment of metastatic colorectal cancer. However, physical incompatibilities between the three drugs prevent a “single solution” intravenous administration of FOLFOX – instead, each drug is separately administered through a central line. A range of adverse events are associated with FOLFOX treatment, including chemotherapy-induced peripheral neuropathy, phlebitis, catheter blockage and sepsis.